

## IN THE CLAIMS

- 1-18. (Canceled)
19. (Currently Amended) A method of inhibiting malignant cell migration ~~and metastasis~~ in a host having a malignancy which is melanoma by administration of a migration-inhibiting effective amount of a composition containing an anti-CCL25 antibody ~~anti-CCL25 antibodies~~ in a pharmaceutically acceptable carrier.
20. (Canceled)
21. (Withdrawn) The method of Claim 19 wherein the host has a leukemia.
22. (Withdrawn) The method of Claim 19 wherein the host has a carcinoma.
23. (Currently Amended) The method of claim 19 wherein the antibody is a ~~antibodies~~ ~~are~~ humanized, human or chimeric antibody ~~antibodies~~.
24. (New) The method of Claim 19, wherein said pharmaceutically acceptable carrier is saline, buffered saline or glucose in saline.
25. (New) The method of Claim 19, wherein said pharmaceutically acceptable carrier is selected from the group consisting of solid support, liposomes and microspheres.
26. (New) The method of Claim 19, wherein said antibody is administered directly to tumor tissue.
27. (New) The method of Claim 19, wherein said antibody is administered directly to tumor bed during an invasive procedure.

28. (New) The method of Claim 19, wherein said antibody is administered intravenously.

29. (New) The method of Claim 19, wherein said antibody is administered subcutaneously.